• E. I. Dubrovskyi Kyiv City Clinical Hospital №4, infectious disease department
  • B. V. Dons’koi Institute of Pediatrics, Obstetrics and Gynecology, National Academy of Medical Sciences of Ukraine
Keywords: COVID-19; immunoglobulin G-class, SARS-CoV-2; antibody; humoral immunity.


Introduction. This article is devoted to determining the level of protective antibodies of the patients at the early and further stages after being suffered from COVID-19.

Materials and methods. On the first stage of the research 66 patients of different age  and gender were examined. All patients, with no exception, had positive PCR results on COVID-19. All patients were  relatively divided into two age groups: from  18  to  39   (n = 39) and from 40 to 65 (n = 27). The light form of disease was detected in 40 patients, the moderate form – in 15 and the severe one – in other 3 patients. 8 people  were ill without symptoms. There were 11 patients hospitalized at the department of infectious diseases of the hospital. Afterwards the level of the antibodies was controlled  on the 60th, 90th and 150th day after the onset. All patients were tested for antibodies to COVID-19 by enzyme-linked immunosorbent assay (ELISA) performed on the equip- ment: enzyme-linked immunosorbent assay Tecan (Austria); PW 40 Microplate Washer (France). ELISA set for serology COVID-19 test system IgG SARS-CoV-2 VitroTest (Ukraine).

Results. Analyzing the data obtained via laboratory research, it can be seen that the immune response to COVID-19 was formed in 82 % of the examined patients.   The maximum level of antibodies, which remains as such up to 40th day.

Results. IgG  increases from 12 to 40 days and then has not changed significantly for 60; 90 and 150 days. Only 4 patients had a noticeable decrease on day 150 (however, they still had a positive level).

Conclusion. IgG levels in patients with Sars-Cov2 remain high for at   least 150 days. The formation of antibodies is not affected by the age difference, neither depends on the severity of the disease.


Download data is not yet available.


Madsen T., Levin N., Niehus K., Law K. et al. Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees // Am. J. Emerg. Med. – 2020 May 3. – pii: S0735- 6757(20)30306-5. – https://www.ncbi.nlm.nih.gov/pubmed/32386808

Demey B., Daher N., François C. et al. Dynamic profile for the detection of anti-SARS- CoV-2 antibodies using four immunochromatographic assays // J. Infect. – 2020 May 7. – pii: S0163-4453(20)30244-9. – https://www.ncbi.nlm.nih.gov/pubmed/32389784

Zhang G., Nie S., Zhang Z. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.J Infect Dis. 2020. May 2. – pii: jiaa229. – https://www.ncbi.nlm.nih.gov/ pubmed/32358956

Wang B., Wang L., Kong X. et al. Long-term coexistence of SARS-CoV-2 with antibody re- sponse in COVID-19 patients // J. Med. Virol. – 2020. Apr 28. – https://www.ncbi.nlm.nih. gov/pubmed/32343415

Zhao R., Li M., Song H. et al. Early detection of SARS-CoV-2 antibodies in COVID-19 pa- tients as a serologic marker of infection // Clin. Infect. Dis. – 2020 May 1. – pii: ciaa523. – https://www.ncbi.nlm.nih.gov/pubmed/32357209

Matricardi P. M., Dal Negro R. W., Nisini R. Thefirst, holistic immunological model of COV- ID-19: implications for prevention, diagnosis, and public health measures // Pediatr. Allergy Immunol. – 2020 May 2. – https://www.ncbi.nlm.nih.gov/pubmed/32359201

Chuan Qin, Luoqi Zhou, Ziwei Hu et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, ciaa 248, 2020 march 12. – https://doi.org/10.1093/cid/ciaa248

Hou H., Wang T., Zhang B. et al. Detection of IgM and IgG antibodies in patients with corona- virus disease 2019 // Clin. Transl. Immunology. – 2020. – Vol. 9, N 5. – P. e01136. – https:// www.ncbi.nlm.nih.gov/pubmed/32382418

Abstract views: 2862
PDF Downloads: 2048
How to Cite
Dubrovskyi, E. I., & Dons’koi, B. V. (2020). DYNAMICS OF COVID-19 SPECIFIC G-CLASS IMMUNOGLOBULINS LEVELS IN PATIENTS AFTER THE RECOVERY. Likars’ka Sprava, (3-4), 3-8. https://doi.org/10.31640/JVD.3-4.2020(1)
Problem article